Whalen Matthew Pratt Acquires 50,000 Shares of MIRA

In a recent insider transaction, Whalen Matthew Pratt acquired 50,000 shares of MIRA on June 12, 2026. The shares were purchased at no cost, with MIRA's stock trading near a spot price of $0.9319. This move is part of a broader trend of insider buying within the company.

Other Institutional Activity in MIRA

Vanguard Capital Management LLC significantly boosted its stake in MIRA by adding 693,912 shares, bringing its total holdings to approximately 693,912 shares valued at $742,486. Geode Capital Management, LLC also increased its position by 18,012 shares, resulting in a total of 290,890 shares worth $311,251. In contrast, Suncoast Equity Management reduced its holdings by 12,644 shares, ending with 90,645 shares valued at $96,990.

MIRA Stock Snapshot

Shares of MIRA are currently trading near $0.9319. The company's stock has seen various institutional investors adjust their positions, reflecting differing levels of confidence and investment strategy.

Insider Buying and Selling at MIRA Pharmaceuticals, Inc.

Several insiders have been active in purchasing shares of MIRA. On June 12, 2026, Edward Clouston MacPherson, Matthew Paul Del Giudice, and Denil Nanji Shekhat each bought 50,000 shares, all at zero cost. Earlier, on December 17, 2025, CEO and Chairman Erez Aminov made a significant purchase of 3,155,170 shares, also at no cost. These transactions suggest a strong belief in the company's potential from within its leadership.

Bottom Line

Insider buying activity at MIRA, including significant purchases by Whalen Matthew Pratt and other executives, highlights a vote of confidence from within the company. While institutional investors like Vanguard Capital Management have also increased their positions, others have reduced their stakes, indicating a mixed sentiment. As always, it's important to remember that these transactions are backward-looking and may not reflect the current positions of the insiders or institutional investors.